84
Kronik Hepatit B
Kaynaklar
1.
Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in
chronic hepatitis B: patterns and natural history. J Clin Gastroenterol 1990; 12: 562-
7.
2.
Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of
hepatitis B. Liver Int.2013 Feb;33 Suppl 1:164-75.
3.
Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody
seroconversion and reversion in Chinese patients with chronic hepatitis B virus
infection. Gastroenterology 1987; 92: 1839-46.
4.
Curry MP, Chopra S. Acute Viral Hepatitis. In: Mandell GL, Bennett JE, Dolin R,
(eds). Principles and Practice of Infectious Diseases. 6 ed. Philadelphia: Churchill
Livingstone. 2005: 1426-1441.
5.
Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B
virus infection. Clin Microbiol Rev 1999;12 (2): 351-366.
6.
Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant
hepatic failure: an assessment of the King’s criteria. J Hepatol 1997;26: 62-68.
7.
Chan HL, Hui Y, Leung NW, et al. Risk factors for active liver disease in HBeAg-
negative chronic hepatitis B virüs infected patients. Am J Gastroenterol 2000; 95:
3547–51.
8.
Sung JJ, Chan HL, Wong ML, et al. Relationship of clinical and virological factors
with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B
virusinfected patients. J Viral Hepat 2002; 9: 229–34.
9.
Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B
virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990;
10: 29–34.
10.
Zhang XQ, Jiang L, You JP, et al. Efficacy of short-term dexamethasone therapy in
acute-on-chronic pre-liver failure Hepatol Res 2011; 41: 46–53.)
11.
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for
patients with chronic hepatitis B and advanced liver disease. N Engl J Med
2004;351:1521–1531.
12.
Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent
hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically
significant or purely ‘‘occult’’? Hepatology 2001;34:194–203.
13.
Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al.
Statements from the Taormina expert meeting on occult hepatitis B virus infection.
J Hepatol 2008;49:652–657.
14.
Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old
and new paradigms. Gastroenterology 2004;127:S56–S61.
15.
Bonilla GR, Roberts LR. The role of hepatitis B virus integrations in the
pathogenesis of human hepatocellular carcinoma. J Hepatol 2005;42:760–777.
16.
Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of
the hepatitis B virus. Carcinogenesis 2011;32:1122–1132)
17.
Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the
management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531–561.
18.
EASL clinical practice guidelines: management of chronic hepatitis B virus
infection. J Hepatol 2012;57:167–185.
19.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology
2009;50:661–662.
